Erectile Dysfunction Drugs Market Research, 2032
The Erectile Dysfunction Drugs Market Size was valued at $2.6 billion in 2022 and is projected to reach $5.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032. Erectile dysfunction (ED) drugs are the medications used to treat the condition of erectile dysfunction, which is the inability to achieve or maintain an erection sufficient for sexual intercourse. Erectile dysfunction drugs work by increasing blood flow to the penis, which helps to create and maintain an erection. The most commonly prescribed erectile dysfunction drugs are phosphodiesterase type 5 (PDE5) inhibitors, which include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra).
Market Dynamics
Growth & innovations in the pharmaceutical industry for the manufacturing of erectile dysfunction drugs, owing to rise in incidences of erectile dysfunction, increase in the geriatric population which are more susceptible to developing erectile dysfunction are the primary factors that drives Erectile Dysfunction Drugs Market Growth. In addition, an increase in demand for erectile dysfunction drugs, rise in R&D activities, and an increase in the prevalence of chronic diseases such as diabetes, hypertension, and obesity further contribute to the market growth.
For instance, according to the National Institutes of Health (NIH), in 2022, erectile dysfunction (ED) is very common condition in U.S. It affects about 30 million men in the U.S. every year. Furthermore, rise in prevalence of psychological disorders such as depression, anxiety, and stress are the primary cause of erectile dysfunction. For instance, according to the American Hospital Association (AHA), in 2020, it was estimated that about 21 million adults are diagnosed with behavioral or emotional disorders in the U.S. This has led to an increase in demand for erectile dysfunction drugs across the globe.
The growth of the erectile dysfunction drugs market is expected to be driven by emerging markets, due to high patient pool, availability of improved healthcare infrastructure, increase in unmet healthcare needs, and rise in prevalence of erectile dysfunction. Furthermore, availability of prescription medication and its generic version for improving erectile function further provides the lucrative Erectile Dysfunction Drugs Market Opportunity in forecast period. For instance, Viagra is a brand name medication for Sildenafil Citrate is also manufactured as a generic medication by Teva pharmaceutical industries and other pharmaceutical companies.
Furthermore, technological advancements, such as the development of new dose medication, collaboration, regulatory approval are driving the growth of the Erectile Dysfunction Drugs Market Size in the forecast period. For instance, in 2020 Teva Pharmaceutical Industries Ltd., had launched ALYQ, a generic version of ADCIRCA1 (tadalafil) tablets, 20 mg in the U.S.
Furthermore, increase in diagnosis and spread of awareness about available medications to treat erectile dysfunction further contribute toward the growth of market. For instance according to National Center for Biotechnology Information (NCBI), before March 2020, the sales of phosphodiesterase-5 inhibitors increased by monthly average of 285,653 units. This is attributed to increase in sale of prescription as well as generic erectile dysfunction drugs from hospital pharmacies and online providers.
On the other hand, various side effects associated with erectile dysfunction drugs limit the adoption of these medications and negatively affect the market growth. For instance, common side effects of erectile dysfunction drugs include headache, facial flushing, and back pain. However, severe side effects are loss of vision, loss of hearing, and painful erection lasting more than 4 hours. On the other hand, erectile drugs can interact with other medications such as nitrates and can cause a severe drop in blood pressure. Therefore, all ED drugs should be taken under the suggestion of healthcare professionals.
Segmental Overview
The erectile dysfunction drugs market is segmented on the basis of product, mode of administration, distribution channel, and region. On the basis of product, the market is classified into sildenafil, Tadalafil, udenafi, avanafil, and others. On the basis of the mode of administration, the market is classified into oral medications and injectable Medication. On the basis of distribution channels, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Product
The Erectile Dysfunction Drugs Industry is segmented into sildenafil, Tadalafil, udenafi, avanafil, and others. The Viagra segment has the largest Erectile Dysfunction Drugs Market Share in 2022, and it is, owing to the increase in the use of prescription Viagra as it is less expensive and available in various dosage strengths such as Viagra (25mg), Viagra (50mg), and Viagra (100mg).
By Mode of Administration
The erectile dysfunction drugs market is segregated into oral medications and injectable Medication. The oral medication segment dominated the global market in 2022 and is anticipated to continue this trend during the Erectile Dysfunction Drugs Market Forecast period. This is attributed to an increase in the adoption of oral drugs such as Cialis, Strendra, Viagra, and others as it can be self-administered and economical which drives the growth of the market .
[MODEOFADMINISTRATIONGRAPH]
By Distribution Channel
The erectile dysfunction drugs market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. The hospital pharmacies segment has the largest Erectile Dysfunction Drugs Market Share in 2022, owing to, rise in prevalence and treatment of erectile dysfunction, the availability of erectile dysfunction drugs through hospital pharmacies, and an increase in s of prescription medication.
By Region
The erectile dysfunction drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major share of the erectile dysfunction drugs market in 2022 and is expected to maintain its lead during the forecast period. This is attributed to, well-established healthcare industry in U.S. and Canada, presence of several major players, such as Pfizer Inc, and Europhins Scientific drive the growth of the market. In addition, rise in the prevalence of diabetes and heart diseases which are the important causes of erectile dysfunction.
This led to an increase in incidences of erectile dysfunction and the demand for erectile dysfunction drug products in the region, which propels the market growth. In addition, the presence of well-established healthcare infrastructure, high purchasing power, and a rise in the adoption rate of dysfunctional drugs are expected to drive market growth. Furthermore, product launches adopted by the key players in this region boost the growth of the market.
Asia-Pacific is expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to the presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, an increase in awareness about erectile dysfunction conditions and available treatments such as Viagra and Cialis drive the growth of the market. In addition, the rise in the smoking population, high prevalence of heart diseases and depression led to an increase in incidences of erectile dysfunction, which, in turn, contributed towards the market growth.
Furthermore, Asia-Pacific offers lucrative opportunities for key players operating in the erectile dysfunction drugs market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of pharmaceutical industries, a rise in disposable income, as well as an increase in healthcare expenditure. In addition, the rise in healthcare access and the high patient pool in the region provide a great opportunity for new entrants in this region.
Competition analysis
Competitive analysis and profiles of the major players operating in the Erectile Dysfunction Drugs Industry, such as Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Bayer AG, Vivus LLC., Adamed, Glenmark Pharmaceuticals Limited, and Cipla Ltd. are provided in this report. There are some important players in the market such as Lupin, Viatris Inc., and others. Major players have adopted product approval, product launch and collaboration as key developmental strategies to improve the product portfolio of the erectile dysfunction drugs market.
Recent Product Approval in the Erectile Dysfunction Drugs Market
In 2021, Glenmark Pharmaceuticals Limited, a world leader in the field of pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for tadalafil tablets in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil is the first line treatment for erectile dysfunction with high success rate of 60-70%. The approval of Tadalafil will help the company to gain strong foothold in erectile dysfunction drugs market.
Recent Collaboration in the Erectile dysfunction drugs Market
In 2021, Greenstone, a subsidiary of Pfizer Inc. collaborated with Roman, a digital men's health clinic. Under this collaboration, Roman will offer Greenstone's generic Viagra (sildenafil) tablets to treat erectile dysfunction. This collaboration will help the company to expand its pharmaceuticals business.
Recent Product Launches in the Erectile Dysfunction Drugs Market
In 2021, Futura Medical PLC launched the erectile dysfunction treatment gel Eroxon in the UK. Eroxon is used to treat erectile dysfunction in men.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the erectile dysfunction drugs market analysis from 2022 to 2032 to identify the prevailing erectile dysfunction drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the erectile dysfunction drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global erectile dysfunction drugs market trends, key players, market segments, application areas, and market growth strategies.
Erectile Dysfunction Drugs Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 5.1 billion |
 Growth Rate | CAGR of 6.5% |
 Forecast period | 2022 - 2032 |
 Report Pages | 417 |
 By Products |
|
 By Mode of Administration |
|
 By Distribution Channels |
|
 By Region |
|
 Key Market Players | Eli Lilly and Company, Bayer AG, Pfizer Inc., Vivus LLC., Sun Pharmaceutical Industries Limited, Cipla Ltd, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Sanofi, Adamed |
Analyst Review
The erectile dysfunction drugs market has witnessed growth, owing to an increase in the incidence of erectile dysfunction, and rise in the prevalence of psychological disorders such stress depression, anxiety and others.
The erectile dysfunction drugs market is expected to witness a steady growth in the future. This is attributed to, increase in the prevalence of erectile dysfunction and rise in awareness regarding the potential benefits of erectile dysfunction treatment. This has led to an increase in demand for erectile dysfunction drugs across the globe. This is anticipated to fuel market growth during the forecast period. Furthermore, the surge in geriatric population that are susceptible to erectile dysfunction further drives the growth of the market. However, side effects associated with erectile dysfunction drugs and lack of awareness and knowledge about erectile dysfunction among the general population are anticipated to hamper the market growth in the upcoming years.
North America is expected to witness the highest growth, in terms of revenue, owing to an increase in cases of erectile dysfunction, robust healthcare infrastructure, presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in use of erectile dysfunction drugs among adult population, rise in adoption of sedentary life style and increase in public–private investments in the healthcare sector.
The base year for the erectile dysfunction drugs market report is 2022
The total market value of the erectile dysfunction drugs market is $2.6 billion in 2022.
The forecast period for erectile dysfunction drugs market is 2023 to 2032.
Top companies such as Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Inc, Sun Pharmaceutical Industries Ltd., Bayer AG, held a high market position in 2022.
The key trends in the erectile dysfunction drugs market are the rise in the prevalence of erectile dysfunction and the rise in the prevalence of psychological disorders.
The factors that restrain the growth of the market is side effects associated with erectile dysfunction drugs.
There are 10 erectile dysfunction drugs market companies are profiled in the report
Yes, the competitive landscape is included in the erectile dysfunction drugs market report.
Loading Table Of Content...
Loading Research Methodology...
